Rilexine® — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Rilexine®

Active ingredient

Cephalexin

Application type

NADA

Sponsor

Virbac AH, Inc.

Applications on record

1

First published

February 22, 2024

Adverse event reports

Source: openFDA VeDDRA

2,777

Reports mentioning this ingredient

April 9, 1999 – March 24, 2026

1,041

Classified serious

per reporter assessment

385

Lack of expected efficacy

resistance signal

205

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “CEPHALEXIN”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Vomiting	308
Accidental exposure	193
Overdose	184
Tablets, Abnormal	66
Lethargy (see also Central nervous system depression in 'Neurological')	50
Uncoded sign	44
Diarrhoea	32
Anorexia	19
Crystalluria	13
Inappetence	12
Behavioural disorder NOS	10
Death by euthanasia	8
Drooling	8
Not eating	8
Loose stool	7
Seizure NOS	7
Panting	7
Dehydration	6
Depression	6
Ataxia	6

Species affected

Source: openFDA VeDDRA

Dog 2,604 Cat 88 Human 3 Ferret 2

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient